Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners

Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a pre-investigational new drug meeting with the US Food and Drug Administration (FDA) for lead asset POLB 001. Cavendish reiterated its 'buy' rating and 19p target price, noting the FDA discussions de-risk the overall development programme by ensuring that the regulator agrees, at least in principle, that the data produced through the clinical programme could support approval.